This Session will discuss financing approaches for developing and commercializing innovative products for diseases with low market incentives. Panel members will explore how funders are thinking about and cooperating to achieve a continuous support where needed as well as the pitfalls of funding only one slice of product development and commercialization.

Key private and government funders will give their views on how funders and companies can ensure sustainable support for infectious disease products through the commercialization, including TB, small molecules, vaccines, and antimicrobial resistance (AMR) products.

Session ID: 545501